According to the Complaint, NextCure, Inc. is a clinical-stage biopharmaceutical company striving to discover and develop novel, first-in-class immunomedicine to treat cancer and other immune-related diseases by restoring normal immune function.

The Complaint alleges that Defendants violated provisions of the Exchange and Securities Acts by misleading investors regarding its leading treatment candidate, NC318. Specifically, the Complaint alleges that statements made by Defendants concerning the effectiveness of NC318, the responses observed in patients treated with NC318, and NC318’s potential to treat patients’ refractory to PD-1 therapies were false and misleading.

On December 8, 2020, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on February 26, 2021. Defendants filed a Motion to Dismiss the amended Complaint on April 27.

On July 12, 2023, the Court issued an Order granting Defendants' Motion to Dismiss. The Clerk of Court was directed to enter judgment and close the case.